TARS Tarsus Pharmaceuticals, Inc.
Healthcare$61.16-1.77%ClosedMarket Cap: $2.63B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.53
P/S
4.92
EV/EBITDA
-66.93
DCF Value
$-436.85
FCF Yield
-1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.4%
Operating Margin
-9.5%
Net Margin
-9.0%
ROE
-14.2%
ROA
-8.3%
ROIC
-11.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $162.1M | 94.2% | $-6.1M | $-7.0M | $— | — |
| Q4 null | $151.7M | 92.8% | $-8.0M | $-8.4M | $— | — |
| FY null | $451.4M | 93.2% | $-71.0M | $-66.4M | $— | — |
| Q3 null | $118.7M | 79.3% | $-14.5M | $-12.6M | $— | — |
| Q2 null | $102.7M | 93.9% | $-22.2M | $-20.3M | $— | — |
| Q1 null | $78.3M | 93.3% | $-26.3M | $-25.1M | $— | — |
| Q4 null | $66.4M | 92.6% | $-24.4M | $-23.1M | $— | — |
| FY null | $183.0M | 93.0% | $-120.6M | $-115.6M | $— | — |
| Q3 null | $48.1M | 93.3% | $-25.2M | $-23.4M | $— | — |
| Q2 null | $40.8M | 92.6% | $-33.3M | $-33.3M | $— | — |
| Q1 null | $27.6M | 94.0% | $-37.7M | $-35.7M | $— | — |
| Q4 2023 | $13.1M | 90.7% | $-44.5M | $-41.9M | $-1.31 | — |